PinnyPeptide

Retatrutide vs Tirzepatide

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

Retatrutide

Weight Management

Lilly's triple-agonist of GLP-1, GIP, and glucagon receptors — the strongest weight-loss data yet reported.

Peptide B

Tirzepatide

Weight Management

Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits.

Typical vial

10 mg

Typical dose

500-12000 mcg

Half-life

~6 days (~144 hours)

FDA status

Not FDA approved. In Phase 3 clinical trials (TRIUMPH progra…

Typical vial

5 mg

Typical dose

2500-15000 mcg

Half-life

~5 days (120 hours)

FDA status

FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound …

Retatrutide effects

  • Triple receptor agonism: GLP-1, GIP, and glucagon
  • Mean ~24% weight loss at 12 mg weekly (Phase 2, 48 weeks)
  • Appetite suppression and delayed gastric emptying (GLP-1 / GIP)
  • Increased energy expenditure and hepatic fat oxidation (glucagon arm)
  • Improved glycemic control in type 2 diabetes
  • Reduction in hepatic fat content (MASH-relevant)

Tirzepatide effects

  • Industry-leading weight loss (up to 22.5% body weight in trials)
  • Superior glycemic control with high rates of HbA1c normalization
  • Dual incretin receptor activation for complementary metabolic benefits
  • Significant reduction in waist circumference and visceral fat
  • Improved cardiometabolic risk factors (lipids, blood pressure)
  • Treatment of moderate-to-severe obstructive sleep apnea in obesity

Retatrutide side effects

  • Gastrointestinal: nausea, vomiting, diarrhea (most common, dose-dependent)
  • Decreased appetite (intended)
  • Constipation
  • Increased heart rate (glucagon-mediated, dose-dependent)
  • Injection-site reactions
  • Risk of pancreatitis (incretin-class concern)
  • Theoretical: thyroid C-cell tumors (incretin-class warning — animal data)
  • Hyperglycemia risk if dose-titration is too rapid (glucagon arm)

Tirzepatide side effects

  • Nausea (most common, particularly during dose escalation)
  • Diarrhea
  • Decreased appetite
  • Vomiting
  • Injection site reactions

Retatrutide dosing ranges

Obesity / weight loss (Phase 2 / 3 protocol)

1-12 mg · Once weekly (SubQ), dose-titrated · Long-term per clinical protocol

Self-experimentation (no clinical guidance)

0.5 mg start, titrate to tolerance · Once weekly · Long-term with careful titration

Tirzepatide dosing ranges

Type 2 diabetes (Mounjaro)

2500-15000 mcg · Once weekly (SubQ) · Ongoing as prescribed

Weight management (Zepbound)

2500-15000 mcg · Once weekly (SubQ, titrated over 20 weeks) · Ongoing as prescribed

Full Retatrutide guide → Full Tirzepatide guide →

Retatrutide vs Tirzepatide — common questions

What is the difference between Retatrutide and Tirzepatide?

Retatrutide: Lilly's triple-agonist of GLP-1, GIP, and glucagon receptors — the strongest weight-loss data yet reported. Typical dose 500-12000 mcg. Tirzepatide: Dual GIP/GLP-1 receptor agonist delivering unprecedented weight loss and metabolic benefits. Typical dose 2500-15000 mcg. Both fall under the Weight Management category.

Can you stack Retatrutide and Tirzepatide?

Stacking Retatrutide with Tirzepatide is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, Retatrutide or Tirzepatide?

Retatrutide is typically dosed: Once weekly (SubQ), dose-titrated for Obesity / weight loss (Phase 2 / 3 protocol); Once weekly for Self-experimentation (no clinical guidance). Tirzepatide is typically dosed: Once weekly (SubQ) for Type 2 diabetes (Mounjaro); Once weekly (SubQ, titrated over 20 weeks) for Weight management (Zepbound).

Are Retatrutide and Tirzepatide FDA approved?

Retatrutide: Not FDA approved. In Phase 3 clinical trials (TRIUMPH program for obesity, SYNERGY-NASH for MASH). FDA submission anticipated 2026-2027 pending Phase 3 readouts. Tirzepatide: FDA approved. Mounjaro (2022) for type 2 diabetes, Zepbound (2023) for chronic weight management, and (2024) for obstructive sleep apnea in adults with obesity.

Related peptide comparisons

aod-9604 vs retatrutideftpp-adipotide vs retatrutidehgh-fragment-176-191 vs retatrutideretatrutide vs semaglutideretatrutide vs survodutideaod-9604 vs tirzepatide

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free